Homepage > Rare diseases > Search

Search for a rare disease

*
(*) mandatory field

Autosomal dominant epidermolytic ichthyosis

Suggest an update
Your message has been sent Your message has not been sent. Please contact an administrator.
Disease definition

A rare keratinopathic ichthyosis (KPI) characterized by a blistering phenotype at birth which progressively becomes hyperkeratotic.

ORPHA:312

Classification level: Disorder

Synonym(s):
  • BCIE
  • Bullous congenital ichthyosiform erythroderma
  • Bullous congenital ichthyosiform erythroderma of Brock
  • Bullous ichthyosis
  • EHK
  • EI
  • Epidermolytic hyperkeratosis
  • Ichthyosis hystrix Brocq type

Source: PubMed ID 31190940

Prevalence: Unknown

Inheritance: Autosomal dominant

Age of onset: Neonatal

ICD-10: Q80.3

ICD-11: EC20.03

OMIM: 113800 620150

UMLS: C0079153

MeSH: D017488

GARD: 1039

Summary
Epidemiology

The prevalence range of all types of KPI is estimated at 1/909,000 in France. The exact worldwide prevalence of epidermolytic ichthyosis (EI) is unknown but is in the 1/2,300,000-4,350,000 range in Japanese and Danish population studies.

Clinical description

Infants present at birth, or shortly after, with erythroderma, mild scaling, severe blistering, and superficial erosions at sites of trauma and flexural areas. Yellow-brown hyperkeratotic plaques, often with mild background erythroderma, develop in the first months of life. The skin has a characteristic dirty looking appearance. Hyperkeratosis has a ridged appearance along skin lines and a cobblestone pattern in the extensor surfaces of joints. It is most often generalized but may be limited to joint flexures, anterior neck, abdominal wall, and infragluteal folds, with relative sparing of the face. Over time, hyperkeratosis worsens and blister formation decreases but may still occur (following skin trauma or during summer). Palmoplantar involvement is seen in some patients and painful blisters tend to develop underneath. Digital contractures and pseudoainhum may occur. Skin is often itchy, smelly, and subject to infections. Other features may include hypohidrosis, scalp scaling, nail dystrophy and abnormal posture. Growth failure may be seen in severe cases. EI persists into adulthood, with hyperkeratosis of variable intensity and extension.

Etiology

The disease is caused by mutations in the genes coding for epidermal suprabasal keratins 1 (KRT1; 12q13.13) and 10 (KRT10; 17q21-q23) that impair keratin intermediate filament formation in the suprabasal keratinocytes. A genotype-phenotype correlation exists, with palmoplantar involvement being generally associated with KRT1, as KRT10 is less expressed in these locations. The position of the mutation may influence the severity of the phenotype

Diagnostic methods

Diagnosis is based on the clinical picture and on histological examination showing hyperkeratosis with orthokeratosis, hypergranulosis, and cytolysis in the upper stratum spinosum and granular layers with characteristic intracellular vacuolization (epidermolytic hyperkeratosis). Electron microscopy shows suprabasal keratinocytes with keratin intermediate filaments clumps and perinuclear keratin clumps in the upper epidermis. Genetic testing confirms the diagnosis.

Differential diagnosis

Differential diagnosis at birth includes other blistering diseases: toxic epidermal necrolysis, inherited epidermolysis bullosa, staphylococcal scalded skin syndrome, incontinentia pigmenti or herpetic infection. In later stages, blistering, ridges along skin lines, and histologic features help to differentiate it from other forms of ichthyoses. Superficial EI usually has a milder phenotype, lacks keratoderma, and has areas with characteristic superficial scaling. Annular epidermolytic ichthyosis is distinguished by the polycyclic and intermittent lesions.

Antenatal diagnosis

Genetic antenatal diagnosis is available.

Genetic counseling

The disease has an autosomal dominant mode of inheritance. Genetic counseling can be offered to affected families when a causing mutation has been identified.

Management and treatment

Treatment is symptomatic. Emollients are often used but have limited efficacy. Topical keratolytics and mechanical removal of scales can improve hyperkeratotic lesions, but may worsen blistering. Some patient, especially those with KRT10 mutation, may benefit from low dose acitretin. Antiseptic washes reduce the bacterial colonization and body odor. Antibiotic therapy is required in cases of bacterial infection.

Prognosis

The severity of the disease is variable. EI impacts the quality of life and social interactions due to skin aspect, pain, walking difficulties, pruritus, body odor, infections, malnutrition and hand contractures. EI can be life-threatening during the neonatal period due to infections and/or dehydration.

Last update: February 2023 - Expert reviewer(s): Dr Eulalia BASELGA TORRES | ERN-Skin*

* European Reference Network

Detailed information

Logo ERN: produced/endorsed by ERN(s) Logo FSMR: produced/endorsed by FSMR(s)

General public
Article for general public
Svenska (2017) - Socialstyrelsen
Guidelines
Emergency guidelines
Français (2018.pdf) - Orphanet Urgences
Clinical practice guidelines
English (2018) - Br J Dermatol Logo ERN
English (2019) - Br J Dermatol Logo ERN
Disease review articles
Clinical genetics review
English (2013.pdf) - Eur J Hum Genet
Patient-Centered Outcome Measures (PCOMs)
Access questionnaires assessing quality of life in this disease (English)
The documents contained in this website are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.